Clinical Trials and Research

Fibroblast growth factor 23 (FGF23), a bone-derived hormone, is emerging as a potential biomarker in cardiovascular disease. However, its role in transthyretin…

CAMBRIDGE, Mass.Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for…

AbstractAmyloidosis associated with mutations in the transthyretin gene is the most common form of hereditary systemic amyloidosis. The onset and phenotype of the…

AbstractTransthyretin cardiac amyloidosis (ATTR-CM) is increasingly recognized as a treatable cause of heart failure, while heart failure with preserved ejection…

AbstractImportance: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disorder caused by destabilization of serum transthyretin (sTTR). Acoramidis, an…

I-evuzamitide positron emission tomography/computed tomography (PET/CT) can help diagnose heart involvement in rare forms of amyloidosis as well as transthyretin-…

ATTR-CM is the zebra hiding among the horses. AI may finally be the tool that finds it. Experts Drs Kevin Alexander and Lily Stern explore what's working, what's…

AboutThe purpose of this study is to investigate the effect of eplontersen compared to placebo on the reduction of serum TTR concentration and long-term safety in…

Transthyretin (ATTR) amyloidosis is a progressive fatal disease caused by the deposition of transthyretin derived amyloid fibrils in various organs [1]. The disease…

Patients enrolled in more recent clinical trials for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) exhibited baseline characteristics consistent with less…